FDA Accepts Xanomeline-Trospium Drug Application for Schizophrenia Treatment

The FDA will decide on the approval of xanomeline-trospium, a dual M1/M4 muscarinic acetylcholine receptor agonist in the central nervous system, for the treatment of schizophrenia patients by September 2024.

Related Keywords

Gordon Lavigne ,Schizophrenia Psychosis Action Alliance ,Drug Administration ,Karuna Therapeutics ,New Drug Application ,Bill Meury ,Psychosis Action Alliance ,Schizophrenia ,Xanomeline Trospium ,Karxt ,Fda ,Food And Drug Administration ,Emergent ,Psychiatry ,